Sanofi (SNY) Other Non-Current Liabilities (2009 - 2026)

Sanofi has reported Other Non-Current Liabilities for 18 years, with the latest figure at $8.0 billion in Q2 2026.

• Quarterly Other Non-Current Liabilities fell 1.18% year-over-year to $8.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.0 billion (down 1.18% YoY) and the FY2025 annual result came in at $7.8 billion, down 9.81% from the prior year.
• Other Non-Current Liabilities climbed to $8.0 billion in Q2 2026 per SNY's latest filing, from $7.8 billion in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $8.9 billion in Q2 2024 and troughed at $1.3 billion in Q4 2022.
• A 5-year average of $7.2 billion and a median of $8.0 billion in 2026 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities decreased 21.99% in 2022, then soared 550.2% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $1.3 billion in 2022, then jumped by 550.2% to $8.2 billion in 2023, then rose by 5.77% to $8.7 billion in 2024, then dropped by 9.81% to $7.8 billion in 2025, then gained by 2.02% to $8.0 billion in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $8.0 billion, $7.8 billion, and $8.1 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.